Lynparza (Olaparib Capsules) and Polatuzumab Vedotin-piiq

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.MONITOR: Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with olaparib. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been reported in patients treated with olaparib. The majority of cases were fatal, and the duration of therapy with olaparib in patients who developed secondary MDS/cancer-therapy related AML varied from less than 6 months to greater than 2 years. All patients had previous chemotherapy with platinum agents and/or other DNA-damaging agents. MANAGEMENT: Caution is advised if olaparib is prescribed with other myelosuppressive agents. Complete blood counts should be performed at baseline and monthly thereafter. Do not start olaparib until patients have recovered from hematologic toxicity caused by previous chemotherapy. For prolonged hematologic toxicities, olaparib should be interrupted and blood counts monitored weekly until recovery. If the levels have not recovered to CTCAE Grade 1 or less after 4 weeks, a haematologist should be consulted for further investigations, including bone marrow analysis and blood sample for cytogenetics. If MDS/AML is confirmed, discontinue olaparib. Patients should be advised to contact their physician if they experience weakness, fatigue, fever, weight loss, infections, shortness of breath, unusual bleeding or bruising, or blood in urine or stool. References "Product Information. Lynparza (olaparib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.

MONITOR: Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with olaparib. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been reported in patients treated with olaparib. The majority of cases were fatal, and the duration of therapy with olaparib in patients who developed secondary MDS/cancer-therapy related AML varied from less than 6 months to greater than 2 years. All patients had previous chemotherapy with platinum agents and/or other DNA-damaging agents.

MANAGEMENT: Caution is advised if olaparib is prescribed with other myelosuppressive agents. Complete blood counts should be performed at baseline and monthly thereafter. Do not start olaparib until patients have recovered from hematologic toxicity caused by previous chemotherapy. For prolonged hematologic toxicities, olaparib should be interrupted and blood counts monitored weekly until recovery. If the levels have not recovered to CTCAE Grade 1 or less after 4 weeks, a haematologist should be consulted for further investigations, including bone marrow analysis and blood sample for cytogenetics. If MDS/AML is confirmed, discontinue olaparib. Patients should be advised to contact their physician if they experience weakness, fatigue, fever, weight loss, infections, shortness of breath, unusual bleeding or bruising, or blood in urine or stool.

Lynparza (Olaparib Capsules)

Generic Name: olaparib

Brand name: Lynparza

Synonyms: Lynparza

What is Lynparza (Olaparib Capsules)?

Polatuzumab Vedotin-piiq

Generic Name: polatuzumab vedotin

Brand name: Polivy

Synonyms: Polatuzumab vedotin, Polatuzumab Vedotin

What is Polatuzumab Vedotin-piiq?